Indubitability, poly (ADP-ribose) polymerase (PARP) inhibitors represented by Olaparib are the most successful representatives and have been used in the clinical treatment of breast cancer, ovarian cancer, prostate cancer, colon cancer, pancreatic cancer, and other cancers (Morganti et al., 2024; Zeng et al., 2024). Here, PARP1 is linked to cancer.